Benign prostatic hyperplasia (BPH) describes the non-malignant enlargement of the
prostate. It is both common and growing in incidence. Treatment is multimodal, involving …

The management of benign prostatic obstruction (BPO) should involve a treatment algorithm
that takes into account prostate size, and patient's symptoms and preference with the aim of …

Major depressive disorder (MDD) is associated with structural and functional brain
abnormalities. MDD as well as brain anatomy and function are influenced by genetic factors …

Aims Premature cardiovascular disease (pCVD) definition varies in literature, with age cut-
offs ranging from 50-65 years. While there is some literature available on pCVD in North …

There are no studies investigating topological properties of resting-state fMRI (rs-fMRI) in
patients who have recovered from psychosis and discontinued medication (hereafter …

Importance The most prescribed class of medications for benign prostatic hyperplasia (BPH)
is α-blockers (ABs). However, the cardiovascular safety profile of these medications among …

Background This study aimed to assess initial results and patient characteristics of prostatic
urethral lift (PUL) compared with those of bipolar transurethral enucleation of the prostate …

Abstract Mitoquinone (MitoQ), a mitochondria-targeted antioxidant, has been used to treat
several diseases. The present study aimed to investigate the therapeutic effects of MitoQ in …

Purpose To determine the difference in the burden of benign prostatic hyperplasia (BPH)
between China and the United States from 1990 to 2019. Methods The prevalence …

Background Benign prostatic hyperplasia (BPH) is common in aging Asian males and is
associated with an excess risk of developing prostate cancer (PCa). However, discussions …